Company Overview
Seer, Inc. operates as a life sciences company dedicated to developing and commercializing products designed to decode the biology of the proteome, aiming to improve human health across a global footprint that includes the United States, China, Australia, Europe, Israel, Japan, and South Africa. The company functions within the Healthcare sector, specifically targeting the Biotechnology industry, which implies a focus on research-intensive development and the commercialization of novel biological solutions rather than traditional manufacturing or retail. At the time of analysis, the company maintains a market capitalization of $93.66M and employs a workforce of 124 individuals, generating annual revenue (TTM) of $16.58M. These financial figures indicate that Seer, Inc. occupies a mid-cap position in the biotechnology landscape, characterized by a relatively small revenue base compared to large-cap pharmaceutical peers, suggesting a stage of operation where capital efficiency and product pipeline execution are critical for scaling operations and achieving profitability.
Financial Health
The company reported revenue of $16.58M for the trailing twelve months, while net income stood at -$73,600,000 and EBITDA reached -$71,888,000. The substantial gap between the positive revenue of $16.58M and the significant net loss of -$73.6M reveals a cost structure dominated by high operating expenses, likely driven by research and development activities typical of early-stage biotechnology firms. Free cash flow for the period was -$27,648,000, indicating that the company's cash burn rate exceeds its operational cash generation, which limits immediate financial flexibility and necessitates reliance on existing cash reserves or external financing. Margin analysis shows a gross margin of 51.1%, suggesting that the cost of goods sold is managed reasonably well, yet the operating margin of -413.8% and profit margin of 0.0% highlight severe inefficiencies or heavy overhead costs relative to revenue. The balance sheet holds $185.90M in cash against $23.65M in debt, resulting in a debt-to-equity ratio of 9.12, which suggests a leveraged capital structure where debt significantly outweighs equity, though the high cash position provides a substantial buffer against this leverage. Liquidity is supported by a current ratio of 12.84, a figure that indicates an extremely strong ability to meet short-term obligations with its current assets. Furthermore, the return on equity is -25.1% and the return on assets is -14.7%, metrics that reveal management is currently utilizing shareholder capital and assets to generate negative returns, reflecting the inherent losses associated with growth-stage biotechnology investments.
Valuation Assessment
Valuation metrics present a complex picture given the company's unprofitability; the trailing P/E ratio is listed as N/A due to losses, while the forward P/E is -1.58. The negative forward P/E implies that the market expects earnings to remain negative or for the company to continue burning cash in the near term rather than approaching profitability. The price-to-book ratio is 0.36, indicating that the market values the company at less than 37% of its book value, which suggests a significant discount to the net asset value often seen in speculative biotech stocks. Alternative valuation metrics show a price-to-sales ratio of 5.65 and an EV/EBITDA of 0.95, suggesting that investors are pricing the company primarily on its revenue potential and cash position rather than current earnings power. Price action over the last year has fluctuated between a 52-week high of $2.41 and a 52-week low of $1.62, providing a trading range within which the current share price must be evaluated relative to its historical volatility. The stock exhibits a beta of 1.66, meaning its price volatility is 66% higher than the broader market, indicating that Seer, Inc. shares are significantly more sensitive to market swings than large-cap indices.
Growth & Income
Revenue growth year-over-year stands at 5.0%, while earnings growth is listed as N/A due to the company's lack of positive net income. The disparity between positive revenue growth and the absence of earnings growth implies that the company is successfully expanding its top line but is unable to convert this growth into profit at the current scale. Regarding income distribution, the company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%. This non-dividend status indicates that Seer, Inc. reinvests all available earnings, or in this case, retains its cash reserves to fund ongoing research and development rather than distributing cash to shareholders. The overall growth and income profile is defined by modest revenue expansion coupled with significant cash consumption, offering no current income yield but relying entirely on capital appreciation potential driven by future product commercialization.